Pharma Mar, S.A. Reports Earnings Results for the Half Year Ended June 30, 2021
July 29, 2021 at 11:03 am EDT
Share
Pharma Mar, S.A. Announced earnings results for the half year ended June 30, 2021. For the half year, the company announced total revenue was EUR 98.692 million compared to EUR 169.110 million a year ago. Operating income was EUR 37.952 million compared to EUR 115.025 million a year ago. Net income was EUR 43.205 million compared to EUR 113.808 million a year ago.
Pharma Mar SA is a Spain-based integrated biopharmaceutical company focused on oncology and committed to research and development (R&D) of antitumor drugs of marine origin. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Companyâs product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The Company is active globally.
PHARMA MAR, S.A. 
